Delmar pharmaceuticals, inc. (DMPI)
CashFlow / Yearly
Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Dec'13Dec'12Jun'12Dec'11Jun'11
Cash flows from operating activities
Loss for the year

-8,048

-11,138

-8,081

-

-

-

-

-

-

-

-

Net loss for the period

-

-

-

8,864

-4,347

6,358

-8,290

-2,400

-18

-1,333

-33

Adjustments to reconcile net loss to net cash used in operating activities
Non-cash derivative issue costs

13

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

16

24

16

10

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

0

-

-

-

-

-

-

Accrued interest

-

-

-

-

2

8

8

7

-

6

-

Change in fair value of derivative liability

433

60

245

-2,341

627

11,529

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

1,324

318

-

0

-

Change in fair value of derivative liability due change in warrant terms

-

-

-

295

-23

-111

-

-

-

-

-

Loss on exchange of warrants

-

-

-

-

-249

-

-

-

-

-

-

Shares issued for services

13

8

564

146

181

-

-

-

-

-

-

Performance stock unit expense

526

48

-

-

-

-

-

-

-

-

-

Warrants issued for services

23

192

81

647

-

-

-

-

-

-

-

Loss on exchange of warrants

-

-

-

-

-

0

-

-

-

-

-

Change in fair value of derivative liability due to tender offer

-

-

-

-

-

-

0

0

-

-

-

Shares issued to Valent for royalty reduction

-

-

-

-

-

-

598

0

-

-

-

Non-cash derivative issue costs

-

-

-

-

-

-

-2,201

0

-

0

-

Units issued for services

-

-

-

-

-

-

0

180

-

95

-

Warrants issued for patents

-

-

-

-

-

-

-

0

-

89

-

Warrants issued for services

-

-

-

-

-

124

124

49

-

0

-

Stock option expense

426

495

124

394

186

1,519

2,146

1,130

-

95

-

Prototype drug product

-

-

-

-

-

-

0

0

-

-

-

Prototype drug product

-

-

-

-

-

-

-

-

-

250

-

Net income (loss) after adjustments of non-cash items

-

-

-

-

-

-3,630

-4,536

-1,351

-

-796

-

Changes in operating assets and liabilities
Prepaid expenses and deposits

-754

-173

1,063

-100

10

13

-

-

-

-

-

Interest, taxes and other receivables

-13

-37

58

-7

16

-7

-34

6

-

24

-

Prepaid expenses

-

-

-

-

-

-

142

14

-

4

-

Accounts payable and accrued liabilities

202

295

598

-178

517

-186

-537

865

-

99

-

Related party payables

164

71

45

-47

35

-181

-338

-70

-

496

-

Total changes in non-cash working capital

-

-

-

-

-

373

-

-

-

-

-

Accounts Receivable

-

-

-

-

-

-

-

-

5

-

-5

Accounts Payable

-

-

-

-

-

-

-

-

2

-

-0

Net cash used in operating activities

-6,327

-9,850

-8,019

-

-3,853

-4,004

-

-

-11

-

-38

Net proceeds from the issuance of units

-

-

-

-

-

-

9,639

671

-

190

-

Deferred costs

-

-

-

-

-

0

0

-90

-

0

-

Series A preferred stock dividend

-

-

-

-

-

0

-

-

-

-

-

Net cash flows from operating activities

-

-

-

-5,145

-

-

-5,520

-578

-

-228

-

Intangible assets - website development costs

-

-12

-20

-16

0

-

-

-

-

-

-

Net cash flows from investing activities

-

-12

-20

-

0

-

-

-

0

-

0

Net cash flows from investing activities

-

-

-

-16

-

-

-

-

-

-

-

Cash flows from financing activities
Net proceeds from the issuance of shares and warrants

3,362

8,945

7,932

2,453

0

-

-

-

-

-

-

Net proceeds from the issuance of Series B Preferred Stock

-

-

-

6,540

0

-

-

-

-

-

-

Net proceeds from the exercise of warrants

720

312

545

579

1,404

2,480

0

0

-

-

-

Series A preferred stock dividend

8

8

8

8

6

-

-

-

-

-

-

Deferred costs

-

-

-

-

550

-

-

-

-

-

-

Net cash provided by financing activities

4,074

9,249

8,468

-

847

2,480

-

-

7

-

0

Proceeds of loan from officer

-

-

-

-

-

-

-

-

7

-

0

Net proceeds from the issuance of common shares

-

-

-

-

-

-

0

0

0

28

0

Net cash flows from financing activities

-

-

-

9,565

-

-

9,639

580

-

219

-

Increase (decrease) in cash and cash equivalents

-2,253

-614

428

4,402

-3,005

-1,523

4,119

2

-

-9

-

Issuance of preferred shares for the settlement of the loan payable with Valent (note 5)

-

-

-

-

-

0

-

-

-

-

-

Reclassification of derivative liability to equity upon the exercise of Investor Warrants (note 7)

-

-

-

-

-

1,110

-

-

-

-

-

Reclassification of derivative liability to equity upon the exchange of Investor Warrants (note 7)

-

-

-

-

-

0

-

-

-

-

-

Reclassification of derivative liability to equity upon the amendment of Dividend Warrants (note 7)

-

-

-

-

-

0

-

-

-

-

-

Reclassification of stock option liability to equity upon the forfeiture of stock options (note 7)

-

-

-

-

-

0

-

-

-

-

-

Issuance of shares for the settlement of accounts payable (notes 7 and 10)

-

-

-

-

-

-

0

253

-

0

-

Issuance of units for the settlement of accounts payable (notes 8 and 10)

-

-

-

-

-

-

0

0

-

23

-

Non-cash share issuance costs (note 9)

-

-

-

-

-

-

6,288

0

-

14

-

Cashless exercise of Placement Agent Warrants (note 9)

-

-

-

-

-

-

239

0

-

0

-

Non-cash acquisition of prototype drug product (note 4)

-

-

-

-

-

-

-

-

-

0

-

Settlement of accounts payable with a loan payable (note 5)

-

-

-

-

-

-

0

0

-

250

-

Exercise of CA$0.50 warrants for no additional consideration (note 7)

-

-

-

-

-

259

241

0

-

0

-

Deferred costs (note 9(f))

-

-

-

-

-

-

90

0

-

0

-

Effects of exchange rates on cash

-

-

-

-

-

-

-

-

0

-

-0

Net increase/ (decrease) in cash

-

-

-

-

-

-

-

-

-3

-

-38

Interest paid

-

-

-

-

-

-

-

-

0

-

0

Income Taxes paid

-

-

-

-

-

-

-

-

0

-

0